How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

677 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients

metabolism, in excess of 14 days (i.e. sibutramine, orlistat, thyroid hormones, systemic corticosteroids and other weight loss/modifying agents) Impaired liver function, defined as ALT (alanine aminotransferase) at least 2.5 times upper limit of normal (central laboratory value measured at screening visit) Inadequately treated high blood pressure defined as Class 2 hypertension or higher (i.e. systolic blood pressure equal to or above 160 mm Hg or diastolic equal to or above 100 mm Hg) in accordance

2015 Clinical Trials

142. Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial. (Abstract)

Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial. The Sibutramine Cardiovascular OUTcomes (SCOUT) trial showed a significantly increased relative risk of nonfatal cardiovascular events, but not mortality, in overweight and obese subjects receiving long-term sibutramine treatment with diet and exercise. We examined the relationship between early changes (both increases and decreases) in pulse rate, and the impact (...) of these changes on subsequent cardiovascular outcome events in both the placebo and sibutramine groups.9804 males and females, aged ⩾55 years, with a body mass index of 27-45 kg m(-)(2) were included in this current subanalysis of the SCOUT trial. Subjects were required to have a history of cardiovascular disease and/or type 2 diabetes mellitus with at least one cardiovascular risk factor, to assess cardiovascular outcomes. The primary outcome event (POE) was a composite of nonfatal myocardial infarction

2015 International Journal of Obesity Controlled trial quality: uncertain

143. Predicting Meaningful Outcomes to Medication and Self-Help Treatments for Binge-Eating Disorder in Primary Care: The Significance of Early Rapid Response. Full Text available with Trip Pro

Predicting Meaningful Outcomes to Medication and Self-Help Treatments for Binge-Eating Disorder in Primary Care: The Significance of Early Rapid Response. We examined rapid response among obese patients with binge-eating disorder (BED) in a randomized clinical trial testing antiobesity medication and self-help cognitive-behavioral therapy (shCBT), alone and in combination, in primary-care settings.One hundred four obese patients with BED were randomly assigned to 1 of 4 treatments: sibutramine (...) , placebo, shCBT + sibutramine, or shCBT + placebo. Treatments were delivered by generalist primary-care physicians and the medications were given double-blind. Independent assessments were performed by trained and monitored doctoral research clinicians monthly throughout treatment, posttreatment (4 months), and at 6- and 12-month follow-ups (i.e., 16 months after randomization). Rapid response, defined as ≥65% reduction in binge eating by the fourth treatment week, was used to predict outcomes.Rapid

2015 Journal of Consulting and Clinical Psychology Controlled trial quality: uncertain

144. Health Beneficial Effects of Krill Oil and Lean and Fatty Fish

1.3-4.0 mmol/L Willingness to eat fish Willingness to not take omega-3 or other dietary supplements during the study. Exclusion Criteria: Pregnancy or lactation Any chronic disease, including diabetes type 1 or 2. CVD or cancer past 6 months Elevated thyroid hormones or TSH levels Elevated total cholesterol (>7.8 mmol/L) or fasting triglycerides (>4.0 mmol/L) Use of prescription drugs that may affect triglycerides (e.g. diabetes drugs, Cyclosporin A, Orlistat and Sibutramine), except statins

2015 Clinical Trials

145. Efficacy and Safety of Gemcabene in Hypercholesterolemic Patients as Monotherapy or in Combination With Atorvastatin

release), psyllium preparation such as Metamucil (>2 tablespoons/day), fibrates and derivatives, bile cholesterol absorption inhibitors including ezetimibe; Any supplement containing plan sterols/stanols (i.e. Benecol, beta‐sitosterol, Cholestatin, Phytoquest, Take Control) or cholestin (i.e. Chinese red yeast, fermented on rice; Hong Qu, Hong Chu, Herbvalin, Ruby Monascus, Monascus purpureus rice); Neomycin (oral); Adrenocortical steroids* Sibutramine (Meridia); Insulin; Orlistat (Xenical

2015 Clinical Trials

146. SATIN: Satiety Innovation. Study 2- University of Aberdeen

obstruction. Psychiatric disorder: severe depression, bulimia, anorexia, schizophrenia, bipolar disorder. Gastrointestinal procedure or surgery in the past three months. Disorders of swallowing, severe dysphagia to food or pills. Pregnancy Medication exclusion criteria Appetite modulator drugs: orlistat, sibutramine, rimonabant. Mood disorder medications: antidepressants, lithium. Others: oral antidiabetics, insulin, digoxin, thyroid hormones, antibiotics, steroids or immunosuppressants, recreational

2015 Clinical Trials

147. Pediatric obesity: Causes, symptoms, prevention and treatment Full Text available with Trip Pro

, hypothalamic melanocortin 4 receptor, and mitochondrial uncoupling proteins, are known to affect body weight. These molecules serve as potential targets for the pharmacological manipulation of obesity. Sibutramine and orlistat are primariliy used for the treatment of adult obesity, which produces modest weight loss, of 3-8% compared to placebo. For children and obese adolescents, metformin is used in the case of insulin resistance and hyperinsulinemia. Octreotide is used for hypothalamic obesity. Bariatric

2015 Experimental and therapeutic medicine

148. Domperidone for Chronic Nausea and Vomiting

, norepinephrine, ondansetron, oxytocin, paliperidone, perflutren lipid microspheres, phentermine, phenylephrine, phenylpropanolamine, protriptyline, pseudoephedrine, ranolazine, ritodrine, roxithromycin, sibutramine, solifenacin, sunitinib, tacrolimus, telithromycin, terbutaline, terfenadine, tolterodine, trimethoprim-sulfa, vandetanib, vardenafil, voriconazole. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact

2015 Clinical Trials

149. A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age

containing St. John's Wort is prohibited within 4 weeks before dosing. Treatment within 4 weeks of dosing with over-the-counter weight loss products or appetite suppressants (including herbal weight loss agents), or within 3 months of dosing with a prescription weight loss drug (eg, phentermine, sibutramine, orlistat) or lipid dissolving injections (eg, Lipodissolve). Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may

2015 Clinical Trials

150. ChemDIS: a chemical–disease inference system based on chemical–protein interactions Full Text available with Trip Pro

. An analysis on maleic acid and sibutramine showed that ChemDIS could be a useful tool for the identification of potential functions, pathways and diseases affected by poorly characterized chemicals.ChemDIS is an integrated chemical-disease inference system for poorly characterized chemicals with potentially affected functions and pathways for experimental validation. ChemDIS server is freely accessible at

2015 Journal of Cheminformatics

151. Systematic guideline search and appraisal, as well as extraction of relevant information on obesity for the DMP module Obesity

general recommendations on learning resources for patients and on the contact frequency of behavioural therapy counselling. Pharmacotherapy and complementary medicine measures ? RCT-based recommendations: Several CPGs demonstrate that an adjuvant therapy with sibutramine or orlistat in patients with a BMI = 30 kg/m² or in patients with a BMI = 27 kg/m² and existing comorbidities can be considered as part of a comprehensive therapy plan. Institute for Quality and Efficiency in Health Care (IQWiG) - 4

2009 Institute for Quality and Efficiency in Healthcare (IQWiG)

152. Weight-reducing drugs may be beneficial in hypertensive patients

Weight-reducing drugs may be beneficial in hypertensive patients PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They Weight-reducing drugs may be beneficial in hypertensive patients Clinical question How effective are weight-reducing drugs in hypertensive patients? Bottom line Although trials of orlistat and sibutramine in patients with elevated blood pressure demonstrated statistically (...) significant decreases in weight, orlistat reduced blood pressure and sibutramine increased blood pressure. Caveat No long term mortality and morbidity RCT evidence is available for these drugs. Trials of rimonabant in this patient population could not be included. Context Orlistat, sibutramine and rimonabant are the main anti- obesity drugs in current use. Orlistat and sibutramine have been approved for long term treatment of obesity throughout much of the world. Rimonabant was approved for use

2011 Cochrane PEARLS

153. J K Aronson – The Hitchhiker’s Guide to Clinical Pharmacology Part 2

Withdrawn Torcetrapib 2006 Cardiotoxicity Withdrawn Sibutramine 2010 Cardiotoxicity Withdrawn Rosiglitazone 2011 Cardiotoxicity Withdrawn Occasionally a drug may be withdrawn but then reintroduced for specific reasons or with specific monitoring. Examples include: clozapine, a dopamine D 2 receptor antagonist used to treat schizophrenia, which was withdrawn in 1985 because of neutropenia, but was then reintroduced in 1989 with a mandatory blood monitoring scheme, in order to detect neutropenia as soon

2016 CEBM blog

154. Finally, the Department of Justice and FDA go after unsafe supplements in a big way

manufacturing practices regulations. Truly, this was an example of . Oh, and Bethel also made medical claims that some of their supplements were able to cure, mitigate, treat, or prevent diseases. It turns out that some of the products marketed as dietary supplements by Bethel contained—you guessed it!—real drugs. These included sibutramine, the active ingredient of Meridia, a drug approved in 1997 to treat obesity that was removed from the market in 2010 because of the risk of serious adverse events

2015 Respectful Insolence

155. Overweight and obesity - use of portion control in management

in management clinical protein in the diet, and • checking that the major carbohydrate sources in the diet have a low glycaemic index (thus supplying a source of energy over a longer period and reducing fluctuations in both blood glucose and insulin concentrations). Pharmacotherapy may assist with appetite control. A Cochrane review found that taking sibutramine resulted in weight loss 4.2 kg greater than the placebo. 34 While appetite suppressant medications may assist with weight loss, they are more

2010 Clinical Practice Guidelines Portal

156. Associations between the GNB3 C825T polymorphism and obesity-related metabolic risk factors in Korean obese women. (Abstract)

of or list at on weight loss with sibutramine. A sample of 111 obese women were divided into T-carriers (CT/TT) or a homozygous CC group, according to the presence of the 825T allele at GNB3. These groups were compared to determine their associations with obesity-related metabolic risk factors, i.e., fasting plasma glucose, serum lipids, serum insulin/insulin resistance, and abdominal fat amounts.The allele frequencies of the GNB3 polymorphism were C allele = 59.5% and T allele = 40.5%. The T allele

2014 Journal of endocrinological investigation Controlled trial quality: uncertain

157. A Proof of Principal Study of Atomoxetine for the Prevention of Vasovagal Syncope

of norepinephrine transport (NET) reuptake with sibutramine and reboxetine (NET inhibitors) prevents syncope on tilt testing by about 80%, and the investigators reported that sibutramine markedly reduced the frequency of vasovagal syncope in 7 of our most symptomatic patients. Sibutramine and reboxetine, for different reasons, are not available in Canada. However atomoxetine is available and is used to help patients with attention deficit disorder. There are no data pertaining to its hemodynamic effects

2014 Clinical Trials

158. Whey Protein Study

(including severe depression, lithium treatment, schizophrenia, severe behavioural disorders) Vegetarians & Vegans Medication Exclusion Criteria: Orlistat (Xenical) Oral antidiabetics, insulin Rimonabant (Acomplia) Digoxin, anti-arrhythmics Sibutramine (Reductil) Tricyclic antidepressants, neuroleptics Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided

2014 Clinical Trials

159. An Electronic Health Records Study of Long-Term Weight Gain Following Antidepressant Use. Full Text available with Trip Pro

hydrochloride, mirtazapine, nortriptyline hydrochloride, paroxetine hydrochloride, venlafaxine hydrochloride, and sertraline hydrochloride. As measures of assay sensitivity, additional index prescriptions examined included the antiasthma medication albuterol sulfate and the antiobesity medications orlistat, phentermine hydrochloride, and sibutramine hydrochloride. Mixed-effects models were used to estimate rate of weight change over 12 months in comparison with the reference antidepressant

2014 JAMA psychiatry (Chicago, Ill.)

160. A Prospective, Randomized, Double-blind, Placebo Controlled Study to Assess the Impact of ORMD-0801 (Insulin Capsules) on the Exogenous Insulin Requirements of Type 1 Diabetics

or immunomodulating agents History of severe or multiple allergies, or known allergy to soy or aprotinin. History of tobacco or nicotine use within 10 weeks prior to screening Patient is on a weight loss program and is not in the maintenance phase, or patient that started weight loss medication (e.g., orlistat or sibutramine) within 8 weeks prior to screening Pregnancy or breast-feeding Patient has a screening visit systolic blood pressure of ≥165 mmHg or diastolic blood pressure of ≥100 mmHg. Patient

2014 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>